English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
TürkçeWest Pharmaceutical (WST) Reports Q4 Earnings: What Key Metrics Have to Say
For the quarter ended December 2025, West Pharmaceutical Services (WST) reported revenue of $805 million, up 7.5% over the same period last year. EPS came in at $2.04, compared to $1.82 in the year-ago quarter.
The reported revenue represents a surprise of +1.35% over the Zacks Consensus Estimate of $794.26 million. With the consensus EPS estimate being $1.83, the EPS surprise was +11.21%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how West Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Change in Organic Revenue: 3.3% versus 1.8% estimated by three analysts on average. Net Sales- Contract-Manufactured Products: $143.2 million compared to the $144.45 million average estimate based on three analysts. The reported number represents a change of +6.2% year over year. Net Sales- Proprietary Products: $661.8 million versus $648.56 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7.8% change. Gross Profit- Proprietary Products: $285.7 million compared to the $257.16 million average estimate based on three analysts. Gross Profit- Contract-Manufactured Products: $18.2 million compared to the $25.76 million average estimate based on three analysts.View all Key Company Metrics for West Pharmaceutical here>>>
Shares of West Pharmaceutical have returned -10.5% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
See Our Newest 5 Stocks Set to Double Picks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).